A placebo-controlled trial of gabapentin in spinal muscular atrophy

R. G. Miller, D. H. Moore, V. Dronsky, Walter G Bradley, R. Barohn, W. Bryan, T. W. Prior, D. F. Gelinas, S. Iannaccone, J. Kissel, R. Leshner, J. Mendell, M. Mendoza, B. Russman, F. Samaha, S. Smith

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

Objective: To evaluate the efficacy of gabapentin in increasing muscle strength of patients with spinal muscular atrophy (SMA). Background: Preclinical data in experimental models of motor neuron disease suggest a neuroprotective effect of gabapentin. Methods: Gabapentin (1200 mg), or placebo, was administered three times daily in a randomized, double-blind trial for 12 months. The primary outcome measure was the average percent change from baseline, based on the measurement of strength in four muscles (elbow flexion and hand grip bilaterally) for each patient. Drug efficacy was examined by comparing the percent change in strength for patients on drug vs. placebo. Secondary efficacy variables included: forced vital capacity (FVC), SMA functional rating scale (SMAFRS), and mini-Sickness Impact Profile (SIP). Results: Eighty-four patients, with type II or III SMA, were enrolled at eight sites across the United States. There were no differences in baseline features. There was no difference between the placebo and drug groups in any outcome measure. Conclusions: This study demonstrates the feasibility of this trial design and provides data for the design of future clinical trials in SMA.

Original languageEnglish
Pages (from-to)127-131
Number of pages5
JournalJournal of the Neurological Sciences
Volume191
Issue number1-2
DOIs
StatePublished - Oct 15 2001

Fingerprint

Spinal Muscular Atrophy
Placebos
Spinal Muscular Atrophies of Childhood
Sickness Impact Profile
Outcome Assessment (Health Care)
Pharmaceutical Preparations
Motor Neuron Disease
Vital Capacity
Muscle Strength
Feasibility Studies
Hand Strength
Neuroprotective Agents
Elbow
Theoretical Models
Hand
Clinical Trials
Muscles
gabapentin

Keywords

  • Clinical trial
  • Gabapentin
  • Placebo-controlled trial
  • Randomized trial
  • Spinal muscular atrophy

ASJC Scopus subject areas

  • Aging
  • Clinical Neurology
  • Surgery
  • Developmental Neuroscience
  • Neurology
  • Neuroscience(all)

Cite this

Miller, R. G., Moore, D. H., Dronsky, V., Bradley, W. G., Barohn, R., Bryan, W., ... Smith, S. (2001). A placebo-controlled trial of gabapentin in spinal muscular atrophy. Journal of the Neurological Sciences, 191(1-2), 127-131. https://doi.org/10.1016/S0022-510X(01)00632-3

A placebo-controlled trial of gabapentin in spinal muscular atrophy. / Miller, R. G.; Moore, D. H.; Dronsky, V.; Bradley, Walter G; Barohn, R.; Bryan, W.; Prior, T. W.; Gelinas, D. F.; Iannaccone, S.; Kissel, J.; Leshner, R.; Mendell, J.; Mendoza, M.; Russman, B.; Samaha, F.; Smith, S.

In: Journal of the Neurological Sciences, Vol. 191, No. 1-2, 15.10.2001, p. 127-131.

Research output: Contribution to journalArticle

Miller, RG, Moore, DH, Dronsky, V, Bradley, WG, Barohn, R, Bryan, W, Prior, TW, Gelinas, DF, Iannaccone, S, Kissel, J, Leshner, R, Mendell, J, Mendoza, M, Russman, B, Samaha, F & Smith, S 2001, 'A placebo-controlled trial of gabapentin in spinal muscular atrophy', Journal of the Neurological Sciences, vol. 191, no. 1-2, pp. 127-131. https://doi.org/10.1016/S0022-510X(01)00632-3
Miller, R. G. ; Moore, D. H. ; Dronsky, V. ; Bradley, Walter G ; Barohn, R. ; Bryan, W. ; Prior, T. W. ; Gelinas, D. F. ; Iannaccone, S. ; Kissel, J. ; Leshner, R. ; Mendell, J. ; Mendoza, M. ; Russman, B. ; Samaha, F. ; Smith, S. / A placebo-controlled trial of gabapentin in spinal muscular atrophy. In: Journal of the Neurological Sciences. 2001 ; Vol. 191, No. 1-2. pp. 127-131.
@article{343d4601b333415a8832a9ab90f9897d,
title = "A placebo-controlled trial of gabapentin in spinal muscular atrophy",
abstract = "Objective: To evaluate the efficacy of gabapentin in increasing muscle strength of patients with spinal muscular atrophy (SMA). Background: Preclinical data in experimental models of motor neuron disease suggest a neuroprotective effect of gabapentin. Methods: Gabapentin (1200 mg), or placebo, was administered three times daily in a randomized, double-blind trial for 12 months. The primary outcome measure was the average percent change from baseline, based on the measurement of strength in four muscles (elbow flexion and hand grip bilaterally) for each patient. Drug efficacy was examined by comparing the percent change in strength for patients on drug vs. placebo. Secondary efficacy variables included: forced vital capacity (FVC), SMA functional rating scale (SMAFRS), and mini-Sickness Impact Profile (SIP). Results: Eighty-four patients, with type II or III SMA, were enrolled at eight sites across the United States. There were no differences in baseline features. There was no difference between the placebo and drug groups in any outcome measure. Conclusions: This study demonstrates the feasibility of this trial design and provides data for the design of future clinical trials in SMA.",
keywords = "Clinical trial, Gabapentin, Placebo-controlled trial, Randomized trial, Spinal muscular atrophy",
author = "Miller, {R. G.} and Moore, {D. H.} and V. Dronsky and Bradley, {Walter G} and R. Barohn and W. Bryan and Prior, {T. W.} and Gelinas, {D. F.} and S. Iannaccone and J. Kissel and R. Leshner and J. Mendell and M. Mendoza and B. Russman and F. Samaha and S. Smith",
year = "2001",
month = "10",
day = "15",
doi = "10.1016/S0022-510X(01)00632-3",
language = "English",
volume = "191",
pages = "127--131",
journal = "Journal of the Neurological Sciences",
issn = "0022-510X",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - A placebo-controlled trial of gabapentin in spinal muscular atrophy

AU - Miller, R. G.

AU - Moore, D. H.

AU - Dronsky, V.

AU - Bradley, Walter G

AU - Barohn, R.

AU - Bryan, W.

AU - Prior, T. W.

AU - Gelinas, D. F.

AU - Iannaccone, S.

AU - Kissel, J.

AU - Leshner, R.

AU - Mendell, J.

AU - Mendoza, M.

AU - Russman, B.

AU - Samaha, F.

AU - Smith, S.

PY - 2001/10/15

Y1 - 2001/10/15

N2 - Objective: To evaluate the efficacy of gabapentin in increasing muscle strength of patients with spinal muscular atrophy (SMA). Background: Preclinical data in experimental models of motor neuron disease suggest a neuroprotective effect of gabapentin. Methods: Gabapentin (1200 mg), or placebo, was administered three times daily in a randomized, double-blind trial for 12 months. The primary outcome measure was the average percent change from baseline, based on the measurement of strength in four muscles (elbow flexion and hand grip bilaterally) for each patient. Drug efficacy was examined by comparing the percent change in strength for patients on drug vs. placebo. Secondary efficacy variables included: forced vital capacity (FVC), SMA functional rating scale (SMAFRS), and mini-Sickness Impact Profile (SIP). Results: Eighty-four patients, with type II or III SMA, were enrolled at eight sites across the United States. There were no differences in baseline features. There was no difference between the placebo and drug groups in any outcome measure. Conclusions: This study demonstrates the feasibility of this trial design and provides data for the design of future clinical trials in SMA.

AB - Objective: To evaluate the efficacy of gabapentin in increasing muscle strength of patients with spinal muscular atrophy (SMA). Background: Preclinical data in experimental models of motor neuron disease suggest a neuroprotective effect of gabapentin. Methods: Gabapentin (1200 mg), or placebo, was administered three times daily in a randomized, double-blind trial for 12 months. The primary outcome measure was the average percent change from baseline, based on the measurement of strength in four muscles (elbow flexion and hand grip bilaterally) for each patient. Drug efficacy was examined by comparing the percent change in strength for patients on drug vs. placebo. Secondary efficacy variables included: forced vital capacity (FVC), SMA functional rating scale (SMAFRS), and mini-Sickness Impact Profile (SIP). Results: Eighty-four patients, with type II or III SMA, were enrolled at eight sites across the United States. There were no differences in baseline features. There was no difference between the placebo and drug groups in any outcome measure. Conclusions: This study demonstrates the feasibility of this trial design and provides data for the design of future clinical trials in SMA.

KW - Clinical trial

KW - Gabapentin

KW - Placebo-controlled trial

KW - Randomized trial

KW - Spinal muscular atrophy

UR - http://www.scopus.com/inward/record.url?scp=0035886619&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035886619&partnerID=8YFLogxK

U2 - 10.1016/S0022-510X(01)00632-3

DO - 10.1016/S0022-510X(01)00632-3

M3 - Article

VL - 191

SP - 127

EP - 131

JO - Journal of the Neurological Sciences

JF - Journal of the Neurological Sciences

SN - 0022-510X

IS - 1-2

ER -